Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

462.200
-0.200-0.04%
Volume:317.90K
Turnover:146.36M
Market Cap:110.47B
PE:-238.59
High:471.000
Open:466.200
Low:456.000
Close:462.400
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.76
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.937
ROE:2.92%
ROA:0.03%
PB:17.70
PE(LYR):-238.59
PS:45.29

Loading ...

Hong Kong Stock Market Update: SKB Bio Surges Over 3% Following Positive Phase 2 Trial Results and Initiation of Phase 3 Study

Stock News
·
Sep 14

Kelun-Biotech Says Phase III Trial Shows Trastuzumab Botidotin Extends PFS vs T-DM1 in HER2+ Metastatic Breast Cancer

Reuters
·
Sep 14

SKB Biopharma's Partner Sees Positive Results from Asthma Drug Trial

MT Newswires Live
·
Sep 08

SKB BIO Announces Positive Phase 2 Interim Data and Phase 3 Launch for Asthma Antibody SKB378/WIN378

Bulletin Express
·
Sep 08

SKB BIO's Asthma Drug Shows Positive Phase 2 Results, Moving to Phase 3

Stock News
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Second Phase 3 Trial Polaris-2 Planned to Begin in First Half of 2027

THOMSON REUTERS
·
Sep 08

Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of Skb378/Win378 in Asthma, and Initiates Phase 3 Study

THOMSON REUTERS
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Skb378/Win378 Well Tolerated with no Treatment-Related Serious Adverse Events

THOMSON REUTERS
·
Sep 08

Sichuan Kelun-Biotech Biopharmaceutical Co - Windward Bio Initiates Phase 3 Study of Skb378/Win378 with Two Twice-Yearly Doses

THOMSON REUTERS
·
Sep 08

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

SKB BIO: DFZQ Disposes of Shares, Long Position Falls to 4.99%

HK Disclosure
·
Sep 04

SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.01%

HK Disclosure
·
Sep 04

HTF Fund Management Increases Stake in SKB BIO with Recent Share Purchase

Stock News
·
Sep 03

SKB BIO: China Universal Asset Management Acquires Shares, Long Position Rises to 5.01%

HK Disclosure
·
Sep 03

SKB BIO Monthly Return: No Share Capital Movement in August 2026, Public Float Compliance Affirmed

Bulletin Express
·
Sep 03

Movement Alert|SKB BIO Falls 3.4% in Regular Trading, Biotechnology Sector Under Broad Pressure

Market Focus
·
Aug 31

Movement Alert|SKB BIO Falls 3.16% in Regular Trading, Trading at HK$519.5

Market Focus
·
Aug 24

Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) After Profitability And Oncology Progress Looks Undervalued

Simply Wall St.
·
Aug 22

Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biotech ETF (03186) Taps Innovation Opportunities Across Hong Kong and US Markets

Stock News
·
Aug 20

SKB BIO Receives Price Target Increase to HK$642 with Buy Rating Maintained by BOCOM International

Deep News
·
Aug 20